Quick Answer
TScan Therapeutics, Inc. reported Total Revenue of $10.32 million for fiscal year 2025.
TScan Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $10.32M +266.7% |
$2.82M -86.6% |
$21.05M +55.5% |
$13.54M +33.5% |
$10.14M +834.7% |
$1.08M |
| Revenue (ASC 606) | $10.32M +266.7% |
$2.82M -86.6% |
$21.05M +55.5% |
$13.54M +33.5% |
$10.14M +834.7% |
$1.08M |
| Net Income | -$129.77M -1.8% |
-$127.50M -42.9% |
-$89.22M -34.7% |
-$66.22M -36.2% |
-$48.62M -86.1% |
-$26.13M |
| Diluted EPS | -$1.00 +12.3% |
-$1.14 +16.2% |
-$1.36 +50.5% |
-$2.75 +34.1% |
-$4.17 | — |
| Total Assets | $228.79M -38.4% |
$371.12M +36.4% |
$272.15M +36.7% |
$199.09M +5.8% |
$188.11M +278.2% |
$49.74M |
| Cash and Equivalents | $152.41M -14.7% |
$178.69M +34.0% |
$133.36M +11.1% |
$120.03M -25.6% |
$161.41M +363.9% |
$34.79M |
| Long-Term Debt | $32.53M +1.4% |
$32.07M +20.1% |
$26.70M -8.8% |
$29.29M | — | — |
| Stockholders Equity | $123.12M -48.9% |
$240.97M +59.7% |
$150.87M +51.7% |
$99.43M -38.2% |
$160.78M +478.6% |
-$42.46M -147.8% |
| R&D Expense | $114.15M +6.3% |
$107.35M +21.8% |
$88.15M +47.4% |
$59.82M +33.1% |
$44.95M +118.5% |
$20.58M |
| Operating Income | -$135.81M -0.7% |
-$134.82M -44.3% |
-$93.46M -40.3% |
-$66.64M -37.0% |
-$48.64M -85.4% |
-$26.23M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $2.51M | +139.4% | -18.4% |
| Revenue (ASC 606) | September 30, 2025 | $2.51M | +139.4% | -18.4% |
| Net Income | September 30, 2025 | -$35.71M | -19.5% | +3.4% |
| Diluted EPS | September 30, 2025 | -$0.28 | -12.0% | +0.0% |
| Total Assets | September 30, 2025 | $262.23M | -24.7% | -12.2% |
| Cash and Equivalents | September 30, 2025 | $169.51M | +27.3% | +0.1% |
| Long-Term Debt | September 30, 2025 | $32.41M | +5.8% | +0.4% |
| Stockholders Equity | September 30, 2025 | $144.02M | -37.1% | -18.5% |
| R&D Expense | September 30, 2025 | $31.69M | +20.7% | -2.9% |
| Operating Income | September 30, 2025 | -$37.05M | -13.6% | +4.1% |
| Shares Outstanding | June 30, 2021 | 1.42M | — | +25.0% |
- TScan Therapeutics, Inc. reported Total Revenue of $10.32 million for fiscal year 2025.
- TScan Therapeutics, Inc. showed an increase of +266.7% in Total Revenue compared to the prior fiscal year.
- TScan Therapeutics, Inc. reported Revenue (ASC 606) of $10.32 million for fiscal year 2025.
- TScan Therapeutics, Inc. showed an increase of +266.7% in Revenue (ASC 606) compared to the prior fiscal year.
- TScan Therapeutics, Inc. reported Net Income of -$129.77 million for fiscal year 2025.
- TScan Therapeutics, Inc. showed a decrease of -1.8% in Net Income compared to the prior fiscal year.
- TScan Therapeutics, Inc. reported Diluted EPS of $1.00 per share (loss) for fiscal year 2025.
- TScan Therapeutics, Inc. showed an increase of +12.3% in Diluted EPS compared to the prior fiscal year.
- TScan Therapeutics, Inc. reported Total Assets of $228.79 million for fiscal year 2025.
- TScan Therapeutics, Inc. showed a decrease of -38.4% in Total Assets compared to the prior fiscal year.
- TScan Therapeutics, Inc. reported Cash and Equivalents of $152.41 million for fiscal year 2025.
- TScan Therapeutics, Inc. showed a decrease of -14.7% in Cash and Equivalents compared to the prior fiscal year.
- TScan Therapeutics, Inc. reported Long-Term Debt of $32.53 million for fiscal year 2025.
- TScan Therapeutics, Inc. showed an increase of +1.4% in Long-Term Debt compared to the prior fiscal year.
- TScan Therapeutics, Inc. reported Stockholders Equity of $123.12 million for fiscal year 2025.
- TScan Therapeutics, Inc. showed a decrease of -48.9% in Stockholders Equity compared to the prior fiscal year.
- TScan Therapeutics, Inc. reported R&D Expense of $114.15 million for fiscal year 2025.
- TScan Therapeutics, Inc. showed an increase of +6.3% in R&D Expense compared to the prior fiscal year.
- TScan Therapeutics, Inc. reported Operating Income of -$135.81 million for fiscal year 2025.
- TScan Therapeutics, Inc. showed a decrease of -0.7% in Operating Income compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: